Skip to main content
OpenTrials
Completed

NCT Number: NCT02528123

VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia

The purpose of this study is to validate the safety and effectiveness of treating myopia (short-sightedness) higher than -10D using small incision lenticule extraction (SMILE) with the VisuMax femtosecond laser.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

London Vision Clinic

London, W1G 7LA, United Kingdom

About this study

Laser refractive surgery (LASIK and PRK) has been established for 25 years to treat myopia (short-sightedness). Over this time, the technology has been significantly improved to enable safe treatment of myopia up to -15D. Improvements including changing the shape of the lens of corneal tissue removed to better match the natural shape, and increasing the diameter of the applied correction to cover larger pupil sizes, have greatly reduced side-effects such as night vision glare and halos. Similarly, safety has been improved by using a laser (femtosecond laser) to create the corneal flap rather than a blade (known as a microkeratome), meaning that the cornea is reliably left with more than the safe amount of tissue.

In 2006, a new method of laser refractive surgery was introduced, small incision lenticule extraction (SMILE), which provides a minimally invasive keyhole method as it avoids the need to create a flap. In SMILE, a single laser (femtosecond laser) is used to make two curved cuts inside the cornea (without breaching the outside) that separate the lens of tissue that needs removing to focus the vision. This lens of tissue is removed in once piece (rather than evaporated as in LASIK) through a small 2mm wide tunnel to the surface.

SMILE has been used to treat short-sightedness up to -10D for more than 200,000 procedures worldwide and has been shown to achieve similar results to LASIK. However, because no flap is needed, this upper part of the cornea can also contribute strength, meaning that the cornea is stronger after SMILE than after LASIK. It is also expected that the accuracy for higher corrections using SMILE would be better than LASIK because the potential inaccuracies associated with excimer lasers (used in LASIK) are eliminated. This study will investigate the results of SMILE for myopia above -10D.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Only patients who are medically suitable for corneal refractive surgery can be included in the study.

  • Subjects should be 21 years of age or older
  • Eyes with high myopia spherical equivalent between -9.00 D up to -14.00 D, with cylinder up to 7.00 D
  • The corrected distance visual acuity will be 20/40 or better in each eye pre-operatively
  • Calculated sub-lenticule thickness (SLT) ≥220 µm
  • Calculated total uncut stromal thickness (TUST) ≥300 µm
  • Contact lens wearers must stop wearing their contact lenses at least four weeks per decade of wear before baseline measurements in case of hard contact lenses and one week before baseline measurements in case of soft contact lenses.
  • Patient will be able to understand the patient information and willing to sign an informed consent
  • Patient will be willing to comply with all follow-up visits and the respective examinations as specified in the flow-chart

Exclusion criteria

  • Previous intraocular or corneal surgery of any kind on the eye being treated
  • Patient not being able to lie flat in a horizontal position
  • Patient not being able to tolerate local or topical anesthesia
  • Autoimmune diseases
  • Sicca syndrome, dry eye
  • Herpes viral (herpes simplex) infections
  • Herpes zoster
  • Diabetes
  • Pregnant or nursing women (or who are planning pregnancy during the study)
  • Patients with a weight of > 135 kg
  • Any residual, recurrent or acute ocular disease or abnormality of the eye, e.g.
  • Cataract
  • Suspected glaucoma or an intraocular pressure > 21 mm of Hg
  • Corneal disease
  • Corneal thinning disorder, e.g. keratoconus,
  • Pellucid marginal corneal degeneration
  • Dystrophy of the basal membrane
  • Corneal oedema
  • Exudative macular degeneration
  • Infection
  • Any residual, recurrent, or active abnormality of the cornea to be treated, e.g.
  • Existing corneal implant
  • Corneal lesion
  • Unstable refraction
  • Connective tissue disease
  • Dry eye

Treatment and study plan

Small Incision Lenticule Extraction

Procedure

The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.

Other names: ReLEx smile, SMILE

Tobramycin and dexamethasone

Drug

Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure

Ofloxacin

Drug

Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure

Proxymetacaine 0.5%

Drug

Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure

Oxybuprocaine 0.4%

Drug

Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure

Primary outcomes

  1. Variability of the Refractive Predicatibility

    Time frame: 1 year postop

    Calculate the standard deviation of the postoperative spherical equivalent, adjusted relative to the intended target, after the SMILE procedure. Analysis performed on the data from the 1 year postoperative visit. An accurate outcome is where the postoperative spherical equivalent is equal to the intended target spherical equivalent. A mean difference less than zero implies the outcome was undercorrected, whereas a mean difference greater than zero implies the outcomes was overcorrected. A smaller standard deviation represents a more accurate and more predictable outcome.

Secondary outcomes

  1. Efficacy of Uncorrected Distance Visual Acuity

    Time frame: 1 year postop

    Measure the uncorrected distance visual acuity achieved after the SMILE procedure relative to the preoperative CDVA for all eyes where the intended target refraction was emmetropia. Analysis performed on the data from the 1 year postoperative visit.

  2. Safety of Corrected Distance Visual Acuity (Change in Corrected Distance Visual Acuity)

    Time frame: 1 year postop

    Assess the change in corrected distance visual acuity (CDVA) before and after the SMILE procedure. Analysis performed on the data from the 1 year postoperative visit.

  3. Predictability of Refractive Correction

    Time frame: 1 year postop

    Measure the postoperative refraction and calculate the deviation from the intended target in terms of spherical equivalent. Mean, standard deviation and range will be calculated. The data will also be analyzed as a scatter plot by plotting the attempted vs achieved spherical equivalent refraction. The data will also be graphically displayed as a histogram. Analysis performed on the data from the 1 year postoperative visit.

  4. Predictability of Refractive Astigmatism Correction

    Time frame: 1 year postop

    Measure the postoperative refractive astigmatism and calculate the deviation from the intended target. Mean, standard deviation and range will be calculated. The data will also be analyzed as a scatter plot by plotting the target induced astigmatism vs the surgically induced astigmatism. The data will also be graphically displayed as a histogram. Analysis performed on the data from the 1 year postoperative visit.

  5. Stability of the Spherical Equivalent Refraction

    Time frame: 3 months and 1 year postop

    Measure the postoperative refraction at 3 months and 12 months after the SMILE procedure and calculate the mean and standard deviation of spherical equivalent refraction for each time point.

  6. Change in Night Vision Disturbances (Questionnaire)

    Time frame: 1 year postop

    Provide the patient with a questionnaire to subjectively grade their quality of vision at night to assess whether this has changed after the SMILE procedure. Analysis performed on the data from the 1 year postoperative visit. A Rasch scale of 0-100 was used. A score of 0 indicates no quality of vision disturbances. A score of 100 indicates severe quality of vision disturbances. The outcome is calculated as the difference between the Rasch score before and after surgery, reported as the change in Rasch score units.

  7. Change in Corneal Higher Order Aberrations

    Time frame: 1 year postop

    Measure the corneal aberrations before and after the SMILE procedure using the Atlas topographer to evaluate the change in corneal aberrations due to the surgery. Analysis performed on the data from the 1 year postoperative visit.

Sponsors and collaborators

Lead sponsor

London Vision Clinic

Other

Registry information

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Aug 19, 2015
Registry last updated
Apr 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.